Backed by neuro enthusiast Arch, upstart BlackThorn tackles some tough targets with $40M round
Arch Venture Partners has fostered a new neurosciences biotech company that will now follow a similar trail to the one being blazed by the high-profile startup Denali. Working with Johnson & Johnson Innovation, Altitude Life Science Ventures, Mercury Fund, Alexandria Real Estate Equities as well as an “undisclosed crossover fund,” the VC is unveiling BlackThorn Therapeutics today, which will now have a $40 million Series A to play with as it looks to help revive a complex and challenging field.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.